Ignite Creation Date:
2024-05-06 @ 6:29 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05679570
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2022-12-04
Brief Title:
Satralizumab in the Treatment of Pulmonary Arterial Hypertension SATISFY-JP Trial
Sponsor:
International University of Health and Welfare
Organization:
International University of Health and Welfare
Study Overview
Official Title:
Satralizumaban Anti-IL-6 Receptor Antibody in the Treatment of Pulmonary Arterial Hypertension Safety and Efficacy Evaluation in Japan -Multicenter Investigator-sponsored Trial-
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Examine the efficacy of satralizumab in patients with pulmonary arterial hypertension PAH with immune-responsive phenotype serum interleukin-6 IL-6 273 pgmL who have an inadequate response to existing drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| jRCT2031210626 | REGISTRY | Japan Registry of Clinical Trials | None |